Gilead Sciences | The Together Campaign
We're excited to be in Rio de Janeiro, attending AIDS 2026
let’s talk
At AIDS 2026, Gilead is proud to share the progress of our leading HIV care research—highlighting multiple advances across treatment and prevention that reflect a more person-centred future of care.
Whether you’re attending the conference or just engaged in the global conversation that's shaping a healthier future for all, your voice matters. Because progress happens through shared purpose—and together, we can help end the HIV epidemic.
Gilead HIV Pipeline
| Clinical Program | Modality | Phase |
|---|---|---|
| HIV Prevention | ||
| Lenacapavir (PURPOSE 365) | PrEP LAI | Phase 3 |
| HIV Treatment | ||
| Bictegravir/lenacapavir oral combination (ARTISTRY-1 & ARTISTRY-2)1 | HIV Oral | Phase 4, NDA submitted |
| Islatravir/lenacapavir oral combination (ISLEND-1 & ISLEND-2)2 | LAO | Phase 3 |
| HIV capsid inhibitor (GS-3107) | LAO | Phase 1 |
| Lenacapavir + teropavimab + zinlirvimabs3 | LAI | Phase 2 |
| HIV INSTI (GS-1219) | LAI | Phase 1 |
| HIV NRTTI (GS-3242) | LAI | Phase 1 |
| HIV Cure | ||
| Teropavimab + zinlirvimab3,4 | Cure | Phase 2 |
| Vesatolimod (FRESH) | Cure | Phase 2 |
| HIV bispecific T-cell engager (GS-8588) | Cure | Phase 1 |
As reported in Gilead’s Q1 2026 Earnings Statement.
https://www.gilead.com/science/pipeline#pipeline_pipeline%20tags=HIV%20Treatment%7C%7CHIV%20Prevention%7C%7CHIV%20Cure
Pipeline shown above as of May 1, 2026. 1. Filed. NDA Submitted. 2. Subject to Gilead and Merck co-development and co-commercialisation agreement. 3. Teropavimab and zinlirvimab are broadly neutralizing antibody (bNAbs). 4. Non-Gilead sponsored trial(s) ongoing. HIV - human immunodeficiency virus, INSTI – integrase strand transfer inhibitor, NRTTI – nucleoside reverse transcriptase translocation inhibitor, LAI – long-acting injectable, LAO – long-acting oral, PrEP – pre-exposure prophylaxis.
Date of approval, May 2026. GFM-UNB-2512